“Biomarking” the transition from genetic risk to kidney disease | Zendy

Etty Kruzel-Davila | Zendy; Karl Skorecki | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

“Biomarking” the transition from genetic risk to kidney disease

Author(s) -

Etty Kruzel-Davila,

Karl Skorecki

Publication year - 2018

Publication title -

kidney international

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.499

H-Index - 276

eISSN - 1523-1755

pISSN - 0085-2538

DOI - 10.1016/j.kint.2018.03.005

Subject(s) - disease , medicine , kidney disease , genotype , population , nephropathy , risk assessment , bioinformatics , intensive care medicine , genetics , biology , environmental health , endocrinology , gene , diabetes mellitus , computer security , computer science

Only some individuals carrying the high-risk APOL1 genotype go on to develop kidney disease phenotypes. In this issue of Kidney International, Nadkarni and colleagues report the associations of several biomarkers with renal outcomes in individuals with high-risk APOL1 genotypes. In the era of precision medicine, these findings should translate into improved longitudinal risk assessment for this high-risk population and might also provide additional insights regarding sites and mechanisms of APOL1 nephropathy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research